| Carrière et al, 200014
|
France |
Amisulpiride (400-1200 mg/d) Haloperidol (10-30 mg/d) |
4-month double-blind, randomized Inpatients |
Baseline: 199 (94 AMI, 105 HAL) 4-month:129 (70 AMI, 59 HAL) |
QLS |
AMI>HAL |
| Colonna et al, 200015
|
France |
Amisulpiride (200-800 mg/d) Haloperidol (5-20 mg/d) |
12-month open-label, randomized Outpatients |
Baseline: 488 (370 AMI, 118 HAL) 12-month: 322 (253 AMI, 69 HAL) |
QLS |
AMI>HAL in QLS total score and in Intrapsychic Foundations, Interpersonal Relations and Instrumental Role domain scores |
| Rosenheck et al 199716, |
USA (multicenter) |
Clozapine (100-900 mg/d) Haloperidol (5-30 mg/d) |
12-month open-label, randomized Treatment-resistant inpatients |
Baseline: 423 (205 CLZP, 218 HAL) 1-year: 178 (117 CLZP, 61 HAL) |
QLS |
CLZPglt;HAL among patients who completed their assigned treatment |
| Essock et al, 199617
|
USA (Connecticut) |
Clozapine Usual care |
2-year open-label, randomized Treatment-resistant inpatients |
Baseline: 227 (138 CLZP, 89 UC) |
QOLI |
CLZP=UC |
| Meltzer et al, 199018
|
USA (Cleveland) |
Clozapine |
6-month open-label Treatment-resistant patients |
Baseline: 38 |
QLS |
Significant improvement in all QLS scores |
| Strakowski et al, 200519
|
USA |
Olanzapine Haloperidol |
1-year double-blind, randomized |
195 first episode (100 OLZ,95 HAL) |
Sf-36 |
OLZ = HAL Significant improvement in5 SF-36 subscales and in the mental summary scale |
| Naber et al, 200520
|
Germany (multicenter) |
Olanzapine (mean dose: 162 mg/d) |
26-week randomized |
99 (49 OLZ, 50 CLZP) |
MLDL SWN |
OLZ = CLZP |
|
|
Clozapine (mean dose: 209 mg/d) |
double-blind |
|
|
|
| Giner et al, 200421
|
Spain (multicenter) |
Olanzapine (mean dose: 13.5 mg/d) |
12-month open label |
372 |
SQLQ QoLI |
Significant improvement in both QoL scales |
| Revicki et al, 199922
|
International (11 countries) |
Olanzapine (5-20 mg/day) Haloperidol (5-20 mg/day) |
52-week double-blind, randomized - 6 week acute phase - 46 week extension phase |
Baseline: 1159 (787 OLZ, 372 HAL) 6-week: 600 OLZ, 228 HAL Outpatients |
QLS SF-36 |
Acute phase: QLS: OLZ>HAL in total, Intrapsychic Foundations and Interpersonal Relation scores. SF-36: OLZ>HAL in MCS, V and MH Extension phase: QLS; OLZ>HAL in total, Intrapsychic Foundations and Instrumental Role scores SF-36: OLZ = HAL |
| Hamilton et al 199823
|
USA (multicenter) |
Olanzapine (5±2.5 mg/d; 10±2.5 mg/d; 15±2.5 mg/d) Haloperidol (15±5 mg/d) Placebo |
24-week double-blind, randomized, placebo controlled inpatients |
Data from 76 patients (16 OLZ-L, 16 OLZ-M, 22 OLZ-H, 12 HAL, 10PBO) |
QLS |
OLZ-M & OLZ-H: significant improvements on QLS total and all subscale scores OLZ-H>PBO on QLS total score OLZ-M>PBO on QLS total and all subscale scores |
| Montes et al, 200324
|
Spain (multicenter - EFESO study) |
Olanzapine (5-30 mg/d) Risperidone (1.5-9.5 mg/d) Haloperidol (3.8-30 mg/d) |
6-month open label without randomization |
182(114 OLZ, 31 RISP, HAL 37) |
EuroQol |
OLZ and RlSP>HAL on EuroQol-VAS scores |
| Gureje et al, 200325
|
Australia and New Zealand |
Olanzapine (10-20 mg/day) Risperidone (4-8 mg/day) |
30-week double-blind, randomized |
Baseline: 65 (32 OLZ, 33 RISP) 30 week: 29 (17 OLZ, 12 RISP) In and outpatiens |
QLS SF-36 |
QLS: OLZ > RISP in the Intrapsychic Foundations subscale score SF-36: OLZ > RISP in the Role Emotional subscale score |
| Ritchie et al, 200326
|
UK |
Olanzapine (9.9 mg/d) Risperidone (1.7 mg/d) |
Open-label, randomized |
Baseline: 66 (36 OLZ, 30 RISP) End: 32 OLZ, 22 RISP |
WHOQOL- BREF |
Significant improvements in OLZ-group in physical. psychological and health satisfaction domains OLZ>RISP in the Psychological domain score |
| Voruganti et al, 200227
|
Canada |
Olanzapine (15-40 mg/d) Risperidone (2-8 mg/d) Quetiapine (200-800 mg/d) |
Naturalistic, single-blind 2-6 years |
Baseline: 150 (50 OLZ, 50 RISP, 50 QUET) End: 118 (44 OLZ, 43 RISP, 31 QUET) |
QLS |
Significant improvements across all groups OLZ=RlSP=QUET |
| Ho et al, 199928
|
USA (Iowa) |
Olanzapine (144 mg/day) Risperidone (57 mg/day) |
6-month open-label |
Baseline: 42 (21 OLZ, 21 RISP) 6-month: 26 (13 OLZ, 13 RISP) Inpatients |
PSYCH-BASE |
OLZ = RISP |
| Tran et al, 199729
|
International (9 countries) |
Olanzapine (10-20 mg/d) Risperidone (4-12 mg/d) |
28-week double-blind, randomized in- and outpatients |
Baseline: 339 (172 OLZ, 167 RISP) 28-week |
QLS |
OLZ & RISP: significant improvements on QLS total and all subscale scores OLZ>RISP on QLS interpersonal relations score |
| Hertling et aI 200330, |
Germany and Austria |
Risperidone (2-6 mg/d) Flupenthixol (4-12 mg/d) |
24-week double-blind, randomized |
Baseline: 153 (77 RISP, 76 FLU) 24-week: 107 (56 RISP, 51 FLU) In and outpatients |
EuroQuol-VAS |
Significant improvement in EuroQuol-VAS in both groups; RISP=FLU |
| Bobes et al, 199831
|
Spain (multicenter) |
Risperidone (3-12 mg/d) |
8-month open-label outpatients |
Baseline: 318 Month-8: 264 |
SF-36 |
At end point significant improvement in all SF-36 subscale scores and summary measures |
| Nasrallah et al, 200532
|
USA |
Long-acting risperidone (25, 50,75 mg/2w) Placebo |
12-week, randomized, double-blind, placebo-controlled |
LA-RISP (93 25 mg/2w, 97 50 mg/2w, 87 75 mg/2w) PBO (92) |
SF-36 |
LA-RISP>PBO in bodily pain, general health, social functioning, role emotional and mental health At week 12 LA-RISP 25 mg/2w reached normal values in all 5F-36 scales but physical functioning |
| Velligan et al, 200333
|
USA (Texas) |
Quetiapine Conventional antipsychotics |
6-month open-label, rater-blinded, randomized |
Baseline; 40 (20 QUET, 20 CAPS) 6-month: 27 (14 QUET, 13 CAPS) |
QLS |
QUET>CAPS |
